Free Newsletter
Teva to cut 315 in Irish plant wind-down
Half of Teva Pharmaceutical's workers at a Waterford, Ireland, plant are getting the axe. In the second plant-layoff announcement this week, the Israeli generics maker told workers that 315 jobs will go, via a mixture of voluntary buyouts and layoffs. The cuts will come within 12 months as Teva stops making drug tablets at the plant.
The plant won't close completely, however; the remaining workers will still turn out inhalers for Teva. And word is that the tablet production isn't going away. It's just being transferred out of Ireland to Hungary, RTÉ News reports.
Teva's job-cuts news comes on the heels of Sanofi-Aventis' announcement that it would shut down a plant in Kansas City, MO. About 370 jobs are on the line there. It's all part of pharma's ongoing efforts to cut costs and streamline production. With two megadeals nearing closure--Merck and Schering-Plough's merger, and Pfizer's buyout of Wyeth--more manufacturing cuts are sure to come.
- read the RTÉ news
- get more from Inside Ireland
Related Articles:
Teva sues over "staggering" auction-rate loss
Rumors: Teva sets its sights on Shire
FDA bars Teva vet drugs on compliance issues
Teva on the hunt for 'major' acquisition
Comments
Teva announce closure of the New Product Development Department in Runcorn, Cheshire.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





